Rentosertib Doses First Patient in China Phase III IPF Trial

Evidence Regulatory + company disclosure · Discovery September 10, 2026 · Importance 4/5 · Direction Positive Summary Insilico Medicine reported first-patient enrollment and dosing in GENESIS-IPF-3, a 320-participant, 47-center China Phase III study of the oral TNIK inhibitor rentosertib in idiopathic pulmonary fibrosis. The 52-week…